FDA

Weekly reads: New FDA guidance, brains, MSCs, senescence

human mouse marmoset brain

This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant […]

Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »

Weekly recommended reads including asymmetric division & chromatin

Asymmetric division and chromatin

One of my favorite types of papers are those on stem cells and chromatin, and a new one in Current Biology caught my eye this week. My own lab website has the URL chromatin.com so that says something. You can also read more about our research here. Recommended reads: chromatin and stem cells, more Asymmetric

Weekly recommended reads including asymmetric division & chromatin Read More »

Translating the FDA’s Q&A on end of stem cell grace period

The Rosetta Stone, The FDA

The FDA grace period for stem cell clinics and others using regenerative medicine products like stem cells is over. It appears the agency is serious about enforcement moving forward. They have released several statements about the end of what they call the “enforcement discretion” period, which just means in English a grace period for marketers

Translating the FDA’s Q&A on end of stem cell grace period Read More »

FDA to end ‘grace period’ on stem cell clinics: agency should ‘go big’ on continued offenders

stem cell clinics map

Stem cell clinics violating federal regulations have been a major problem for the FDA. Next month the FDA faces a historic moment on this problem. A grace period for clinics to become FDA compliant ends in May. Even so, it appears that hundreds of clinics will remain non-compliant after that. Some of the worst clinics

FDA to end ‘grace period’ on stem cell clinics: agency should ‘go big’ on continued offenders Read More »

FDA OK’s more COVID-19 efforts of unproven stem cell clinics

The-FDAs-big-COVID-stem-cell-clinic-can-of-worms-small

In my view, it seems likely that the FDA has opened a big can of worms by starting to clear the COVID-19 trials and programs of for-profit stem cell clinics and other related firms. OK to Stemedica trial The FDA just approved another such effort, this one by the firm Stemedica. You can read more about

FDA OK’s more COVID-19 efforts of unproven stem cell clinics Read More »

Weekly reads: FDA news, goosebump stem cells, MSCs, autophagy

Levy-et-al-MSCs-Science-Advances

Ready for the latest recommended weekly reads in the world of stem cells and the regenerative medicine space including a bunch of important new FDA posts & changes? This post has quite a lot on the FDA since it had a very big week with several new items of major importance to the cellular and regenerative

Weekly reads: FDA news, goosebump stem cells, MSCs, autophagy Read More »

Getting 30 F grades? FDA Strongly Warns Exosome Firm EUCYT

EUCYT-CEO-Travis-Bird

The FDA dropped a lengthy, extremely critical warning letter on a supplier of unproven exosome product called EUCYT Laboratories. For broader context, exosome therapy has somehow burst onto the scene when there’s no good data yet in my view to back up its use in the clinic. The FDA is taking notice with letters already sent

Getting 30 F grades? FDA Strongly Warns Exosome Firm EUCYT Read More »

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.